Skip to main content
Erschienen in: Journal of Cancer Survivorship 3/2019

08.05.2019

Use of complementary/integrative methods: cancer survivors’ misconceptions about recurrence prevention

verfasst von: Ted Gansler, Sara Strollo, Elizabeth Fallon, Corinne Leach

Erschienen in: Journal of Cancer Survivorship | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Many cancer survivors use complementary and alternative health methods (CAM). Because we are unaware of high-level evidence supporting CAM for preventing cancer recurrence, we studied post-treatment survivors who use CAM to assess (1) the percentage who included preventing recurrence as a motive for using CAM, (2) characteristics of survivors who use CAM intended to prevent recurrence, and (3) CAM domains associated with use for recurrence prevention.

Methods

We studied participants in the American Cancer Society’s Study of Cancer Survivors-I (nationwide study of adult survivors) who used CAM (excluding osteopathy, yoga, tai chi, or qi gong users, as well as anyone whose only reported CAM was prayer/meditation). Multivariable logistic regression was used to examine associations of independent variables with CAM use for recurrence prevention.

Results

Among 1220 survivors using CAM, 14.8% reported recurrence prevention as a reason for CAM use (although only 0.4% indicated this was their only reason). The following were independently associated with odds of CAM use to prevent recurrence: not being married/in a marriage-like relationship (OR = 1.53, 95% confidence interval [CI] 1.05–2.23), using mind–body (OR = 1.65, 95% CI 1.08–2.51) or biologically based (OR = 4.11, 95% CI 1.96–8.59) CAM and clinically relevant fear of recurrence (OR = 1.96, 95% CI 1.38–2.78).

Conclusions

Approximately 1/7 of survivors who use CAM have unrealistic expectations about CAM reducing recurrence risk. This expectation is strongly associated with the use of biologically based CAM.

Implications for Cancer Survivors

Patient education should support informed decisions and realistic expectations regarding any complementary/integrative or mainstream/conventional clinical intervention.
Literatur
1.
Zurück zum Zitat Gansler T, Kaw C, Crammer C, Smith T. A population-based study of prevalence of complementary methods use by cancer survivors: a report from the American Cancer Society’s studies of cancer survivors. Cancer. 2008;113(5):1048–57.CrossRefPubMed Gansler T, Kaw C, Crammer C, Smith T. A population-based study of prevalence of complementary methods use by cancer survivors: a report from the American Cancer Society’s studies of cancer survivors. Cancer. 2008;113(5):1048–57.CrossRefPubMed
2.
Zurück zum Zitat Bell RM. A review of complementary and alternative medicine practices among cancer survivors. Clin J Oncol Nurs. 2010;14(3):365–70.CrossRefPubMed Bell RM. A review of complementary and alternative medicine practices among cancer survivors. Clin J Oncol Nurs. 2010;14(3):365–70.CrossRefPubMed
3.
Zurück zum Zitat Goldstein MS, Brown ER, Ballard-Barbash R, Morgenstern H, Bastani R, Lee J, et al. The use of complementary and alternative medicine among California adults with and without cancer. Evid Based Complement Alternat Med. 2005;2(4):557–65.CrossRefPubMedPubMedCentral Goldstein MS, Brown ER, Ballard-Barbash R, Morgenstern H, Bastani R, Lee J, et al. The use of complementary and alternative medicine among California adults with and without cancer. Evid Based Complement Alternat Med. 2005;2(4):557–65.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther. 2012;11(3):187–203.CrossRefPubMed Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther. 2012;11(3):187–203.CrossRefPubMed
5.
Zurück zum Zitat King N, Balneaves LG, Levin GT, Nguyen T, Nation JG, Card C, et al. Surveys of cancer patients and cancer health care providers regarding complementary therapy use, communication, and information needs. Integr Cancer Ther. 2015;14(6):515–24.CrossRefPubMed King N, Balneaves LG, Levin GT, Nguyen T, Nation JG, Card C, et al. Surveys of cancer patients and cancer health care providers regarding complementary therapy use, communication, and information needs. Integr Cancer Ther. 2015;14(6):515–24.CrossRefPubMed
6.
Zurück zum Zitat Luo Q, Asher GN. Complementary and alternative medicine use at a Comprehensive Cancer Center. Integr Cancer Ther. 2017;16(1):104–9.CrossRefPubMed Luo Q, Asher GN. Complementary and alternative medicine use at a Comprehensive Cancer Center. Integr Cancer Ther. 2017;16(1):104–9.CrossRefPubMed
7.
Zurück zum Zitat Mao JJ, Palmer CS, Healy KE, Desai K, Amsterdam J. Complementary and alternative medicine use among cancer survivors: a population-based study. J Cancer Surviv. 2011;5(1):8–17.CrossRefPubMed Mao JJ, Palmer CS, Healy KE, Desai K, Amsterdam J. Complementary and alternative medicine use among cancer survivors: a population-based study. J Cancer Surviv. 2011;5(1):8–17.CrossRefPubMed
8.
Zurück zum Zitat Davis EL, Oh B, Butow PN, Mullan BA, Clarke S. Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review. Oncologist. 2012;17(11):1475–81.CrossRefPubMedPubMedCentral Davis EL, Oh B, Butow PN, Mullan BA, Clarke S. Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review. Oncologist. 2012;17(11):1475–81.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Sohl SJ, Weaver KE, Birdee G, Kent EE, Danhauer SC, Hamilton AS. Characteristics associated with the use of complementary health approaches among long-term cancer survivors. Support Care Cancer. 2014;22(4):927–36.CrossRefPubMed Sohl SJ, Weaver KE, Birdee G, Kent EE, Danhauer SC, Hamilton AS. Characteristics associated with the use of complementary health approaches among long-term cancer survivors. Support Care Cancer. 2014;22(4):927–36.CrossRefPubMed
11.
Zurück zum Zitat Greenlee H, DuPont-Reyes MJ, Balneaves LG, et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. 2017;67(3):194–232.CrossRefPubMedPubMedCentral Greenlee H, DuPont-Reyes MJ, Balneaves LG, et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. 2017;67(3):194–232.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Deng GE, Rausch SM, Jones LW, Gulati A, Kumar NB, Greenlee H, et al. Complementary therapies and integrative medicine in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e420S–36S.CrossRefPubMed Deng GE, Rausch SM, Jones LW, Gulati A, Kumar NB, Greenlee H, et al. Complementary therapies and integrative medicine in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e420S–36S.CrossRefPubMed
13.
Zurück zum Zitat Deng GE, Cassileth BR, Cohen L, et al. Integrative Oncology Practice Guidelines. J Soc Integr Oncol. 2007;5(2):65–84.CrossRefPubMed Deng GE, Cassileth BR, Cohen L, et al. Integrative Oncology Practice Guidelines. J Soc Integr Oncol. 2007;5(2):65–84.CrossRefPubMed
14.
Zurück zum Zitat Berger AM, Mooney K, Banerjee CB. Cancer-related fatigue version 1.2019. NCCN Clinical Practice Guidelines in Oncology 2019; nccn.org. Accessed March 21, 2019. Berger AM, Mooney K, Banerjee CB. Cancer-related fatigue version 1.2019. NCCN Clinical Practice Guidelines in Oncology 2019; nccn.org. Accessed March 21, 2019.
15.
Zurück zum Zitat Ettinger DS, Berger MJ, Aston J, et al. Antiemesis version 1.2019. NCCN Clinical Practice Guidelines in Oncology 2019; nccn.org. Accessed March 21, 2019. Ettinger DS, Berger MJ, Aston J, et al. Antiemesis version 1.2019. NCCN Clinical Practice Guidelines in Oncology 2019; nccn.org. Accessed March 21, 2019.
16.
Zurück zum Zitat Riba MB, Donovan KA, Andersen B, et al. Distress Management version 2.2019. NCCN Clinical Practice Guidelines in Oncology 2019; nccn.org. Accessed 21 March 2019. Riba MB, Donovan KA, Andersen B, et al. Distress Management version 2.2019. NCCN Clinical Practice Guidelines in Oncology 2019; nccn.org. Accessed 21 March 2019.
17.
Zurück zum Zitat Swarm RA, Paice JA, Anghelescu DL. Adult cancer pain version 2.2019. NCCN Clinical Practice Guidelines in Oncology 2019; nccn.org. Accessed March 21, 2019. Swarm RA, Paice JA, Anghelescu DL. Adult cancer pain version 2.2019. NCCN Clinical Practice Guidelines in Oncology 2019; nccn.org. Accessed March 21, 2019.
18.
Zurück zum Zitat Verhoef MJ, Balneaves LG, Boon HS, Vroegindewey A. Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients: a systematic review. Integr Cancer Ther. 2005;4(4):274–86.CrossRefPubMed Verhoef MJ, Balneaves LG, Boon HS, Vroegindewey A. Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients: a systematic review. Integr Cancer Ther. 2005;4(4):274–86.CrossRefPubMed
19.
Zurück zum Zitat Munstedt K, Kirsch K, Milch W, Sachsse S, Vahrson H. Unconventional cancer therapy--survey of patients with gynaecological malignancy. Arch Gynecol Obstet. 1996;258(2):81–8.PubMed Munstedt K, Kirsch K, Milch W, Sachsse S, Vahrson H. Unconventional cancer therapy--survey of patients with gynaecological malignancy. Arch Gynecol Obstet. 1996;258(2):81–8.PubMed
20.
Zurück zum Zitat Risberg T, Kaasa S, Wist E, Melsom H. Why are cancer patients using non-proven complementary therapies? A cross-sectional multicentre study in Norway. Eur J Cancer. 1997;33(4):575–80.CrossRefPubMed Risberg T, Kaasa S, Wist E, Melsom H. Why are cancer patients using non-proven complementary therapies? A cross-sectional multicentre study in Norway. Eur J Cancer. 1997;33(4):575–80.CrossRefPubMed
21.
Zurück zum Zitat Chrystal K, Allan S, Forgeson G, Isaacs R. The use of complementary/alternative medicine by cancer patients in a New Zealand regional cancer treatment centre. N Z Med J. 2003;116(1168):U296.PubMed Chrystal K, Allan S, Forgeson G, Isaacs R. The use of complementary/alternative medicine by cancer patients in a New Zealand regional cancer treatment centre. N Z Med J. 2003;116(1168):U296.PubMed
22.
Zurück zum Zitat Smith T, Stein KD, Mehta CC, Kaw C, Kepner JL, Buskirk T, et al. The rationale, design, and implementation of the American Cancer Society’s studies of cancer survivors. Cancer. 2007;109(1):1–12.CrossRefPubMed Smith T, Stein KD, Mehta CC, Kaw C, Kepner JL, Buskirk T, et al. The rationale, design, and implementation of the American Cancer Society’s studies of cancer survivors. Cancer. 2007;109(1):1–12.CrossRefPubMed
23.
Zurück zum Zitat Campbell PT, Patel AV, Newton CC, Jacobs EJ, Gapstur SM. Associations of recreational physical activity and leisure time spent sitting with colorectal cancer survival. J Clin Oncol. 2013;31(7):876–85.CrossRefPubMed Campbell PT, Patel AV, Newton CC, Jacobs EJ, Gapstur SM. Associations of recreational physical activity and leisure time spent sitting with colorectal cancer survival. J Clin Oncol. 2013;31(7):876–85.CrossRefPubMed
24.
Zurück zum Zitat Maliniak ML, Patel AV, McCullough ML, et al. Obesity, physical activity, and breast cancer survival among older breast cancer survivors in the cancer prevention study-II nutrition cohort. Breast Cancer Res Treat. 2018;167(1):133–45.CrossRefPubMed Maliniak ML, Patel AV, McCullough ML, et al. Obesity, physical activity, and breast cancer survival among older breast cancer survivors in the cancer prevention study-II nutrition cohort. Breast Cancer Res Treat. 2018;167(1):133–45.CrossRefPubMed
25.
Zurück zum Zitat Wang Y, Jacobs EJ, Gapstur SM, Maliniak ML, Gansler T, McCullough ML, et al. Recreational physical activity in relation to prostate cancer-specific mortality among men with nonmetastatic prostate cancer. Eur Urol. 2017;72(6):931–9.CrossRefPubMed Wang Y, Jacobs EJ, Gapstur SM, Maliniak ML, Gansler T, McCullough ML, et al. Recreational physical activity in relation to prostate cancer-specific mortality among men with nonmetastatic prostate cancer. Eur Urol. 2017;72(6):931–9.CrossRefPubMed
26.
Zurück zum Zitat Simard S, Savard J. Fear of cancer recurrence inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence. Support Care Cancer. 2009;17(3):241–51.CrossRef Simard S, Savard J. Fear of cancer recurrence inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence. Support Care Cancer. 2009;17(3):241–51.CrossRef
27.
Zurück zum Zitat Simard S, Savard J. Screening and comorbidity of clinical levels of fear of cancer recurrence. J Cancer Surviv. 2015;9(3):481–91.CrossRefPubMed Simard S, Savard J. Screening and comorbidity of clinical levels of fear of cancer recurrence. J Cancer Surviv. 2015;9(3):481–91.CrossRefPubMed
28.
Zurück zum Zitat Judson PL, Abdallah R, Xiong Y, Ebbert J, Lancaster JM. Complementary and alternative medicine use in individuals presenting for care at a comprehensive cancer center. Integr Cancer Ther. 2017;16(1):96–103.CrossRefPubMed Judson PL, Abdallah R, Xiong Y, Ebbert J, Lancaster JM. Complementary and alternative medicine use in individuals presenting for care at a comprehensive cancer center. Integr Cancer Ther. 2017;16(1):96–103.CrossRefPubMed
29.
Zurück zum Zitat Wanchai A, Armer JM, Stewart BR. Complementary and alternative medicine use among women with breast cancer: a systematic review. Clin J Oncol Nurs. 2010;14(4):E45–55.CrossRefPubMed Wanchai A, Armer JM, Stewart BR. Complementary and alternative medicine use among women with breast cancer: a systematic review. Clin J Oncol Nurs. 2010;14(4):E45–55.CrossRefPubMed
30.
Zurück zum Zitat Clarke TC. The use of complementary health approaches among U.S. adults with a recent cancer diagnosis. J Altern Complement Med. 2018;24(2):139–45.CrossRefPubMed Clarke TC. The use of complementary health approaches among U.S. adults with a recent cancer diagnosis. J Altern Complement Med. 2018;24(2):139–45.CrossRefPubMed
31.
Zurück zum Zitat Bishop FL, Yardley L, Lewith G. Developing a measure of treatment beliefs: the complementary and alternative medicine beliefs inventory. Complement Ther Med. 2005;13(2):144–9.CrossRefPubMed Bishop FL, Yardley L, Lewith G. Developing a measure of treatment beliefs: the complementary and alternative medicine beliefs inventory. Complement Ther Med. 2005;13(2):144–9.CrossRefPubMed
32.
Zurück zum Zitat Bode AM, Dong Z. Toxic phytochemicals and their potential risks for human cancer. Cancer Prev Res (Phila). 2015;8(1):1–8.CrossRef Bode AM, Dong Z. Toxic phytochemicals and their potential risks for human cancer. Cancer Prev Res (Phila). 2015;8(1):1–8.CrossRef
33.
Zurück zum Zitat Bjelakovic G, Nikolova D, Gluud C. Antioxidant supplements and mortality. Curr Opin Clin Nutr Metab Care. 2014;17(1):40–4.PubMed Bjelakovic G, Nikolova D, Gluud C. Antioxidant supplements and mortality. Curr Opin Clin Nutr Metab Care. 2014;17(1):40–4.PubMed
34.
Zurück zum Zitat Cohen PA. Hazards of hindsight--monitoring the safety of nutritional supplements. N Engl J Med. 2014;370(14):1277–80.CrossRefPubMed Cohen PA. Hazards of hindsight--monitoring the safety of nutritional supplements. N Engl J Med. 2014;370(14):1277–80.CrossRefPubMed
35.
36.
Zurück zum Zitat Nahin RL, Barnes PM, Stussman BJ. Insurance coverage for complementary health approaches among adult users: United States, 2002 and 2012. NCHS Data Brief. 2016;(235):1–8. Nahin RL, Barnes PM, Stussman BJ. Insurance coverage for complementary health approaches among adult users: United States, 2002 and 2012. NCHS Data Brief. 2016;(235):1–8.
Metadaten
Titel
Use of complementary/integrative methods: cancer survivors’ misconceptions about recurrence prevention
verfasst von
Ted Gansler
Sara Strollo
Elizabeth Fallon
Corinne Leach
Publikationsdatum
08.05.2019
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 3/2019
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-019-00762-0

Weitere Artikel der Ausgabe 3/2019

Journal of Cancer Survivorship 3/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.